MYCN and neuroblastoma: To characterize the relevance of the differential apoptotic response seen in the combined ABT-199/MLN8237 treatment between MYCN-amplified and MYCN-WT neuroblastoma cells (Figure 5A), we treated cell lines with each inhibitor alone or in combination and assayed viability after 5 days (Figures 5F and 5G).